Objective. State prescription drug monitoring programs (PDMPs) can help detect individuals with multiple provider episodes (MPEs; also referred to as doctor/pharmacy shopping), an indicator of prescription drug abuse and/or diversion. Although unsolicited reporting by PDMPs to prescribers of opioid analgesics is thought to be an important practice in reducing MPEs and the potential harm associated with them, evidence of its effectiveness is mixed. This exploratory research evaluates the impact of unsolicited reports sent by Massachusetts' PDMP to the prescribers of persons with MPEs.
Methods. Individuals with MPEs were identified from PDMP records between January 2010 and July 2011 as individuals having Schedule II prescriptions (at least one prescription being an opioid) from four or more distinct prescribers and four or more distinct pharmacies within six months. Based on available MA-PDMP resources, an unsolicited report containing the patient's 12-month prescription history was sent to prescribers of a subset of patients who met the MPE threshold; a comparison group closely matched on demographics and baseline prescription history, whose prescribers were not sent a report, was generated using propensity score matching. The prescription history of each group was examined for 12 months before and after the intervention.
Results. There were eighty-four patients (intervention group) whose prescribers received an unsolicited report and 504 matched patients (comparison group) whose prescribers were not sent a report. Regression analyses indicated significantly greater decreases in the number of Schedule II opioid prescriptions (P < 0.01), number of prescribers visited (P < 0.01), number of pharmacies used (P < 0.01), dosage units (P < 0.01), total days' supply (P < 0.01), total morphine milligram equivalents (MME; P < 0.01), and average daily MME (P < 0.05) for the intervention group relative to the comparison group. A post hoc analysis suggested that the observed intervention effects were greater for individuals with an average daily dose of less than 100 MMEs.
Conclusions. This study suggests that PDMP unsolicited reporting to prescribers can help reduce risk measures in patients' prescription histories,
Introduction
Prescription Drug Monitoring Programs (PDMPs) are recognized as a key tool in federal, state, and local efforts to address prescription drug abuse and misuse [1, 2] . PDMPs are state online databases to which pharmacies and other dispensers report dispensed outpatient controlled substance prescription information. Forty-nine states currently have an operational program. In nearly all programs, prescribers and pharmacists can register to obtain patients' controlled substance prescription histories, which can inform their clinical decisions. The use of PDMP data by prescribers appears to be effective at modifying their behavior toward patients potentially abusing prescription medications or obtaining controlled substance prescriptions from multiple providers, referred to in this paper as multiple provider episodes (MPEs) [3, 4] . This type of behavior is also referred to as doctor shopping in the literature [3, 4] . There is also some evidence that prescriber use of PDMP data may reduce prescription drug-related overdose deaths, but more definitive research in this area is needed [5] .
Despite this recognition, PDMPs are often underutilized to improve public health outcomes and address prescription drug abuse [6] [7] [8] [9] [10] . To augment solicited reports on patient prescription histories, many PDMPs proactively analyze their data and send unsolicited reports of patient prescription history to prescribers and/ or pharmacists, calling their attention to prescription information of which they may not otherwise have been aware [11] . While unsolicited reporting is regarded as an important PDMP practice in helping to reduce prescription drug misuse, abuse, and diversion, evidence for its effectiveness is limited [11] . Several non-peer-reviewed studies suggest that unsolicited reporting may have beneficial effects. For example, states with PDMPs that generate unsolicited reports were found to exhibit slower growth in Schedule II prescriptions of pain reliever and stimulant sales and reduced growth in treatment admissions for prescription drug abuse compared with states with PDMPs that do not [12] . Further, decreases in the number of individuals meeting MPE thresholds have been observed in Nevada and Wyoming following the sending of unsolicited reports to their prescribers [13] [14] [15] . However, a more recent study examining effects on drug overdose mortality rates and sales of prescription opioids found no difference between states with PDMPs that generate unsolicited reports and states with PDMPs that do not [16] .
Although several of these studies suggest an effect of unsolicited reporting, they have important methodological limitations. The cross-state analyses of Simeone and Holland [12] and Paulozzi et al. [16] did not control for differences between states that may affect the outcomes and excluded the many PDMPs that have become operational since 2008. Separate initiatives conducted by the Nevada and Wyoming PDMPs sent unsolicited reports on all patients who met certain thresholds, precluding the generation of comparison groups on whom unsolicited reports were not sent [13] [14] [15] . Consequently, these observational studies did not account for changes in prescription histories that might have occurred in the absence of an unsolicited report, such as those due to regression to the mean.
Recent studies by a managed care program and a health plan, rather than a PDMP, were able to employ a randomized control trial design and found a greater reduction in the number of prescribers and pharmacies used and opioid prescriptions for patients whose prescription histories had been proactively provided to their prescribers, relative to control patients [17, 18] . While addressing an important limitation of prior studies of unsolicited or proactive reporting, these studies were nevertheless not able to examine prescriptions from outof-program prescribers and pharmacies (often paid for by cash)-a method used by drug-seeking individuals to avoid detection-thereby possibly overestimating intervention effects.
We conducted an exploratory study assessing the effects of unsolicited reporting to prescribers of opioid analgesics by the Massachusetts PDMP (MA-PDMP), comparing the pre-/postprescription histories of an intervention group (patients on whom unsolicited reports are sent to their prescribers) with those of a matched comparison group. By employing a matched comparison group design, we were able to examine and account for changes in patient prescription histories occurring in the absence of unsolicited reporting. In addition, by using data from a state PDMP, we were able to include all controlled substance prescriptions, in particular those paid for by cash, to measure the effects of unsolicited reporting. As a result, this study contributes to the evidence base of the effectiveness of PDMP unsolicited reporting to prescribers of opioid analgesics and specifically addresses limitations in previous nonpeer-reviewed analyses that did not include a comparison group.
Methods

Setting
The MA-PDMP collects prescription data from Massachusetts pharmacies, including community, hospital outpatient, clinic, and out-of-state mail order pharmacies that deliver to patients in Massachusetts. Although established in 1992, the MA-PDMP only began collecting patient-identifying information in 2009. This change enabled the program to begin sending unsolicited reports to prescribers of patients who met certain thresholds for numbers of prescribers and numbers of pharmacies used. The program began unsolicited reporting in the spring of 2010 on a small random proportion of the patients who met the thresholds (stratified on varying threshold levels), allowing for the retrospective construction of a matching comparison group of patients on whom no reports were sent.
Study Design
Massachusetts state law restricts the use of the PDMP or PDMP data for purposes other than public health surveillance and evaluation, precluding a randomized controlled study design. Thus, the evaluation was carried out as an observational study in which a comparison group was generated using propensity score matching. The prescription history for 12 months prior (baseline) and 12 months subsequent to (follow-up) the intervention was analyzed for each group. This analysis focused on Schedule II prescriptions. Because data for Schedules III-V became available in the follow-up period (after January 2011), we were able to examine the postintervention Schedule III-V prescription histories for those individuals in the study who had no Schedule II prescriptions in the follow-up period.
The study was approved by the Brandeis University Institutional Review Board (IRB). The Massachusetts Department of Health's IRB Committee determined that the study was part of a program evaluation and its formal IRB approval was unnecessary.
Selection of Subjects
Selection of Individuals with MPEs from the MA-PDMP Database
Individuals who met the MPE threshold of having obtained Schedule II prescriptions (at least one of them must have been an opioid) from four or more distinct prescribers and four or more distinct pharmacies within a six-month time period (for additional perspective on the selection criterion, see [6] ) were identified from the MA-PDMP database using a threshold report. For purposes of the analysis, chain store pharmacies at different addresses were counted as distinct pharmacies. An individual was identified by first name, last name, and date of birth. The database was queried multiple times during the time period that unsolicited reports were being actively sent out to prescribers (between January 2010 and July 2011). On average, approximately 3,600 individuals met the specified MPE threshold during each six-month interval.
Selection of Subjects for the Intervention Group
Because of limited program resources, it was not possible to generate and send PDMP reports for every patient who met the specified MPE threshold. Consequently, only a small subset of individuals who met the MPE criterion were selected. The intervention group was selected randomly among the eligible cohort who exceeded the MPE threshold. A simple random number generator was used for the selection process.
Once an individual was randomly selected, additional queries were run for that individual using possible nicknames or wild card characters for the first and last name to account for possible pharmacy errors/inconsistencies or intentional fraudulent reporting of identifier information.
Example 1: Robert Smith with DOB January 15, 1966, was identified using threshold report and randomly selected as a case. The PDMP database would also be searched for a first name of "Bob" or "Rob*" and last name of "Smith" with DOB January 15, 1966.
Example 2: Katherine Jones with DOB of June 15, 1975 , was identified and selected as a case. The PDMP database would also be searched for "Catherine" or "Kat*" and last name would be searched for "Jones*" to capture possible hyphenated names.
When slight variations/differences in the first or last name were identified so that there was not an identical match, other identifier fields were examined (e.g., address, customer ID, and common prescribers) to verify with reasonable certainty that all prescription records were associated with the selected individual who met the MPE threshold. Compared with the number of prescription records associated with an individual based on exact matching of patient identifying information, this procedure added only small percentage to the total of prescription records associated with individuals who met the MPE threshold.
A hard copy unsolicited report of the individual's last 12-month prescription history was sent via postal mail to the prescriber's work address provided in the Federal Drug Enforcement Agency (DEA) database. The cover letter indicated that the Department of Public Health thought this prescription history should be brought to the prescriber's attention. The cover letter also provided contact information for any questions or corrections the prescriber may wish to communicate. The unsolicited report was sent to each prescriber that the individual visited. Reports were not sent to out-of-state prescribers or if the prescriber was identified as a hospital/ facility rather than an individual (this can occur when a resident/intern or other practitioner uses a hospital DEA number). Prior to sending reports to prescribers, prescription records for those selected subjects were first reviewed by the MA-PDMP staff to assess whether there may be a clinically legitimate explanation for visiting multiple prescribers (e.g., cancer patients who see different specialists or multiple providers from the same group practice). This was done by reviewing the address and looking up the specialty of the prescribers in Folio Med (a subscription-based reference database of all practicing physicians in the Northeast) and excluding those patients who appeared to have legitimate reasons for visiting multiple prescribers.
Selection of Subjects for Comparison Group
Subjects in the comparison group were selected from the large pool of individuals who had four or more prescribers and four or more pharmacies in a six-month period and for whom reports were not sent. As noted above, we were not able to prospectively randomly assign individuals who met the MPE threshold to an intervention and comparison group. Although individuals were selected to the intervention group using random assignment, because this assignment occurred at several times, we could not be assured that the intervention group taken as a whole represented a randomly selected group. For example, individuals in one period may have used more prescribers on average than individuals in another period. To help control for possible selection effects, we employed propensity score matching (PSM) [19, 20] . PSM is used when randomization is not feasible to reduce selection bias in the construction of intervention and comparison groups. In particular, if the intervention and comparison groups differ on the outcome variables by changes in which the effects of unsolicited reporting are to be measured, then methods used to assess these changes, such as multiple regression, may not be valid [21, 22] .
The PSM procedure in this study was a one-to-many case-control within caliper with replacement design, which has been found to be the most effective PSM procedure for removing selection bias [21, 23] .
Covariates were combined into a single propensity score using logistic regression predicting intervention group membership. Demographics included age, gender, and county. Baseline outcome measures included number of prescriptions; number of prescribers; number of pharmacies; total days' supply of opioids; total opioid dosage units; total morphine equivalents; and average daily MME. Additionally, the model included all two-way variable interactions between age, number of prescriptions, number of prescribers and number of pharmacies as well as a three-way interaction between number of prescriptions, number of prescribers and number of pharmacies. Individuals from the intervention group were then matched with other individuals among potential controls using a nearest-neighbor procedure with a caliper of one-quarter of one standard deviation (0.04) of the propensity score mean [23] .
The procedure resulted in a comparison group of six individuals closest in propensity score to each of the individuals in the intervention group. 2 In the case of ties, individuals were selected to the comparison group at random from those with equal scores. This procedure yielded comparable groups on baseline prescription measures and demographics and reduced the threat to design validity posed by selection effects. We assessed differences between the two groups at baseline on all outcome variables used by means of t tests.
Baseline Prescription History
For the intervention group, an unsolicited report (including the most recent 12 months of all Schedule II opioid prescription records) was sent to prescribers. For subjects in the comparison group, the baseline period was matched to the 12-month period of the corresponding subject in the intervention group. On average, unsolicited reports were sent about two months after the most recent month of data reported in the individual prescription history. This lag period was in place because at the time pharmacies were only required to report PDMP data on a monthly basis. An additional month was necessary to account for correction files that are submitted to correct errors from pharmacy submissions.
Follow-up Prescription History
The follow-up period for each subject was also 12 months. We used a three-month lag period from the last month of the baseline period to the first month of the follow-up period to ensure that the follow-up period did not include prescription records prior to the prescribers having received the unsolicited report and having an opportunity to see the patient again (see Figure 1 ).
An additional month of lag time was added because it could take several weeks for a subject to see a prescriber again. In some instances, however, the patient may only see the prescriber one time (e.g., emergency department [ED] prescribers are often targeted by drug seekers who only visit one time and then move onto the next ED).
Outcome Data Used for Analysis
We examined measures from the subjects' history that have been found to be associated with MPEs, opioid abuse, and/or overdose involving prescription opioids [6, [24] [25] [26] [27] [28] [29] . These variables included the number of prescriptions, number of prescribers, number of pharmacies, quantity supplied (solid dose 3 ), and number of days' supply (solid dose). To adjust for differences in opioid potency, we calculated the morphine milligram equivalents (MME; solid dose only). 4 The total and
Evaluation of Unsolicited PDMP Reporting average daily dose (i.e., average daily opioid dose during the study period for all opioid prescriptions combined) were calculated for each subject for the baseline and follow-up periods. Post hoc, to explore possible interactions between average daily dosage and the intervention, we stratified subjects by average daily dosage in two ways: 1) into those with less than 100 MME/ d and those with 100 MME/d or more, based on the reported association between this dosage level and the likelihood of drug overdose death [30] ; and 2) into those with less than 90 MME/d vs 90 MME/d or more, a threshold suggested in recent Centers for Disease Control and Prevention opioid prescribing guidelines [31, 32] .
Statistical Analysis
Microsoft Access and Excel were used to generate individual-and aggregated-level data. Summary statistics for the specified MPE measures were generated in Excel. Statistical analyses were conducted using SPSS version 23.
The statistical significance of differences between the two groups was assessed using a difference-indifferences approach with ordinary least square multiple regression. To reduce skewness in the variable distributions, we transformed each measure by taking the natural logarithm. 5 For each measure, the follow-up period value was regressed on the baseline value, with a dichotomous variable indicating membership in the intervention group, and controlling for age and gender. We examined the outcome measures at baseline for collinearity; for each outcome measure assessed, we controlled for the other measures that were not mutually collinear. The regressions allowed us to control for any residual differences between the intervention and comparison groups not fully accounted for in the propensity score matching. We examined q-q plots of the errors of each regression for any remaining correlation with the respective outcome variable.
Results
Study Population
During the first six months of 2010 (January to June), approximately 3,600 individuals (about 0.8% of all individuals who received at least one Schedule II opioid prescription during that time period) met or exceeded the four prescriber and four pharmacy MPE threshold. 6 These individuals received 48,489 Schedule II opioid prescriptions (3.8% of total Schedule II opioid prescriptions reported to the MA-PDMP during the time period), amounting to 2,648,868 dosage units (3.2% of the Schedule II opioid solid dosage units reported to the MA-PDMP during the time period).
Eighty-four individuals who met the MPE threshold were selected from the total MPE cohort (intervention group), and their prescribers received an unsolicited report between January 2010 and July 2011. Individuals were identified each month, and reports sent on a monthly basis during that period. Five hundred and four matched subjects for whom no unsolicited report was sent (comparison group) were identified from the MPE cohort using propensity score matching. Table 1 provides summary demographic characteristics and baseline prescription measures for each of these two groups. Of the outcome measures examined, the two groups significantly differed at baseline only on average number of Schedule II opioid prescriptions; comparison group members had an average of 42.9 prescriptions during the 12-month baseline period, compared with 48.3 prescriptions for the intervention group (P ¼ 0.04) ( Table 1) .
During the baseline period, subjects in the intervention group received Schedule II opioid prescriptions from an average of 18.5 distinct prescribers and 11 distinct pharmacies ( Table 1 ). The average solid dose dispensed in the full baseline period (i.e., number of pills/tablets) was approximately 2,300 dosage units. This represents a total of approximately 51,000 MME and an average of 473 days' supply per individual. Although the intervention group represented 2.3% of individuals who met the MPE threshold in the MA-PDMP, it accounted for an estimated 8.4% of Schedule II prescription opioids and 7.3% of total solid dosage units associated with individuals who met the MPE threshold. Table 2 presents the distribution of prescribers and pharmacies at baseline and follow-up for the intervention and comparison groups. Although the two groups did not differ at baseline in these distributions, they did differ at follow-up for distributions of both prescribers and pharmacies. There was a shift in both groups toward fewer prescribers and fewer pharmacies. However, the shift toward fewer prescribers and fewer pharmacies was more pronounced for the intervention group. Young et al. Table 3 presents the results of multiple regression analyses of baseline to follow-up changes in outcome measures, testing for an intervention group effect relative to the comparison group and controlling for demographic and other outcome measures at baseline. Standardized regression coefficients are presented. All outcome measures decreased to a significantly greater extent (P < 0.01) for the intervention group relative to the comparison group. Adjusted R 2 values for the regression models ranged from 0.14 to 0.43. Each outcome variable at follow-up was significantly associated with its baseline value. This association was greatest for total opioid dosage and average daily dosage, suggesting greater resistance to change in those measures.
Pre-Post Changes in Outcome Measures
Seven intervention group and 17 comparison group individuals did not receive any Schedule II prescriptions during the follow-up period. Because of the newly expanded state requirements of monitoring Schedule II-V prescriptions in the follow-up period, we were able to examine whether individuals with no Schedule II prescriptions during the follow-up period had other controlled substance (i.e., Schedule III-V) prescriptions. Three intervention group and five comparison group individuals had received Schedule III-V prescriptions. For these latter individuals, we interpreted the zero Schedule II prescriptions as representing a valid measure, and consequently retained them in the sample to be analyzed. We explored removing the remaining four intervention group members, their 24 matched comparison group members, and the remaining 12 comparison group members from the sample to be analyzed because we could not exclude the possibility that they had moved from the area, were deceased, were incarcerated, or were otherwise unable to receive Schedule II prescriptions during the follow-up period. Regression analyses conducted on this modified sample yielded results that did not materially differ from those presented in Table 3 .
To explore intervention effects on average daily dosage, in light of the relative lack of change in this measure, we conducted a post hoc stratification of the study groups based on this measure. We stratified the intervention group into a subgroup A, with average daily dosage at baseline of less than 100 MME, and a subgroup B, with average daily dosage at baseline of 100 MME or more. Subgroup A consisted of 66 individuals, and subgroup B consisted of 18 individuals. We then identified the matched comparison group members for each subgroup and reran the regression analyses on each subgroup. Results of these regressions, presented in Table 4 , A and B, indicate that the intervention had a pronounced and statistically significant effect for individuals with average daily dosages of less than 100 MME (Table 4A ) and no observable effect for individuals with average daily dosages greater than or equal to 100 MME (Table 4B) . We explored other dosage values for stratification. At a stratification cutoff of 90 MME, we again found a significant intervention effect on all outcome measures for the subgroup with dosage of less than 90 MME, but found some effects of the intervention for the subgroup with dosage greater than or equal to 90 MME. For this latter subgroup, we found an intervention effect on number of prescribers (P < 0.05), number of pharmacies (P < 0.01), and on total opioid dosage (P < 0.05). 
Discussion
This study adds to the limited evidence base of the effectiveness of PDMP unsolicited reporting in reducing indicators of patients' risk for prescription opioid misuse and abuse. As noted in the Results section, we found a statistically significant effect of the intervention on all seven patient risk measures examined. Two aspects of the findings are worth discussion. First, consistent with prior studies of proactive reporting in a managed care N ¼ 588. MME ¼ morphine milligram equivalent. * P < 0.05. ** P < 0.01. *** P < 0.001. † Each variable x (except age and gender) has been transformed by the monotonic natural logarithm transformation to ln(x þ .01) to reduce its skewness. ‡ Total MMEs was collinear with daily average MMEs (r ¼ 0.9), so it was omitted from all regressions except when it was the dependent variable. Sample restricted to intervention group members with daily average MME < 100 at baseline and propensity score-matched comparison group members. Baseline measures are included as predictors when not collinear with baseline counterpart to follow-up outcome measure. N ¼ 462; 66 from intervention group, 396 from propensity score matches in comparison group. MME ¼ morphine milligram equivalent. * P < 0.05. ** P < 0.01. *** P < 0.001. Sample restricted to intervention group members with daily average MME ! 100 at baseline and propensity score matched comparison group members. Baseline measures are included as predictors when not collinear with baseline counterpart to follow-up outcome measure. N ¼ 126; 18 from intervention group, 108 from propensity score matches in comparison group. MME ¼ morphine milligram equivalent. * P < 0.05. ** P < 0.01. *** P < 0.001.
program and a health plan, subjects not receiving the intervention exhibited a decline in numbers of prescribers and pharmacies used, albeit of lower magnitude than the intervention group. One explanation is that prescribers who received unsolicited reports communicated with other prescribers, raising overall awareness of the prescription drug abuse problem. Consequently, prescribers who had not received unsolicited reports may have been more sensitized to the issue and more cautious about prescribing controlled drugs. For Massachusetts prescribers who received unsolicited reports in 2010, the novelty of receiving patient prescription histories lends weight to the plausibility of this explanation. We explored this explanation further by examining the overlap of prescribers between the two groups. We found that at baseline 10% of the intervention group prescribers were also prescribers for the comparison group. In the follow-up period, 9% of intervention group prescribers also prescribed to comparison group members. However, we found no difference in prescribing changes in the follow-up period between individuals with a prescriber who also prescribed to the intervention group and individuals without such a prescriber. Nevertheless, this overlap in prescribers may have contributed to a general increase in awareness that the MA-PDMP was proactively examining patient prescription histories. Alternatively, individuals may be able to sustain high levels of prescription drug misuse/ abuse activity only for a short time, as suggested by Daubresse et al. [18] , and tend to revert to the mean. Additional research is needed to better understand factors underlying declines in these outcome measures in the comparison group.
When we restricted the stratified study sample based on average daily dosage of 100 MME, we found evidence that the intervention effects appeared to have been greater for individuals with average daily dosages of less than 100 MME and no evidence of an effect for those with daily dosages above that amount. While this latter finding represents an exploratory post hoc analysis, to our knowledge it is the first reported finding of a differential effect of unsolicited reporting on patients stratified by a measure of risk. In addition to confirming this finding, further research is needed to clarify the mechanisms by which unsolicited reporting may produce its effects, more fully examine different stratification values, and explore alternative interventions for MPE patients with higher average daily dosages of opioid analgesic who may be at risk. For example, a rigorous study that follows up on prescriber actions taken after receiving unsolicited reports or alert notifications on high-risk patients may shed more light on the extent to which these types of programmatic activities result in prescribers "firing" the patient, creating a possible patient safety concern, or alternatively possibly better coordinated care and substance abuse referrals.
The presumption with unsolicited reporting is that providing prescribers with patient prescription histories they may not have been aware of enables these prescribers to act on that information to improve patient care. Although unsolicited reporting is one approach PDMPs can take to increase prescriber awareness of and use of PDMP data, other approaches are available. For example, a number of states, including Massachusetts, have now enacted "mandatory use" laws requiring providers to register with the PDMP and query the PDMP under specified conditions. The three earliest states to enact the most stringent versions of these lawsKentucky, New York, and Tennessee-have reported substantial declines in multiple provider episodes in the months following enactment [33] . However, there is currently no data we are aware of as to whether unsolicited reporting has an effect over and above that apparently achieved by the mandatory use laws. Future research is needed to assess the efficacy of combining multiple approaches to increasing prescriber use of PDMP data.
This study provides two important strengths relative to prior studies of unsolicited reporting. First, it includes a matched comparison group to control for patient behavior in the absence of unsolicited reporting; and second, in using PDMP data, the analysis includes prescriptions paid for with cash, an important category of prescriptions to include in light of the finding that more than 40% of prescriptions obtained by opioid drug seekers were paid for with cash transactions [34] .
The study has several limitations. First, it is exploratory in nature, and the design and development of methodology (e.g., the selection of the comparison population) occurred after individuals were selected for the intervention. Based on available PDMP resources, on only a small proportion of the individuals who met the MPE threshold were unsolicited reports sent to their prescribers. Because these individuals were selected randomly at different times, the overall sample of individuals included in the intervention group may not represent a random sampling from the population of individuals meeting the MPE threshold. Consequently, the findings in relation to this sample may not be generalizable to the population of individuals meeting the MPE threshold.
Second, the construction of the matched comparison group based on propensity score matching depended on variables available in the PDMP data. Variables such as race, ethnicity, and medical history were not available for use in matching. Because such variables may be associated with prescription history, their inclusion would be expected to improve the efficiency of the propensity score matching and the comparability between the intervention and comparison groups.
Third, the study was confined to a single state. Although only including data from one state has the benefit of removing possible confounding factors associated with state differences, the timing of the study may limit the generalizability of its findings to unsolicited reporting by other PDMPs. As noted earlier, although in operation since 1992, the Massachusetts PDMP only began collecting patient identifying information in 2009. This information enabled the PDMP to conduct unsolicited reporting for the first time. It also enabled the PDMP, for the first time, to provide prescribers online access to its database; this latter enhancement began in the fall of 2010. Thus, for at least some prescribers who received the unsolicited reports on patients followed in this study, these reports represented the first patient prescription histories they had been able to obtain without submitting a formal written request to the program. For this reason, the unsolicited reports may have been more impactful than they would have been had the prescribers been able to register with and query the PDMP directly about their patients. It is to be noted, though, that in states where prescribers have online access to PDMP prescription histories, including Massachusetts from late 2010, prescribers have tended to be slow to adopt this technology [35] .
A further difference between state PDMPs is the method used to identify which prescription records belong to the same patient, sometimes called "clustering." Because PDMP data typically do not include a unique patient identifier, such as Social Security Number, PDMPs must match, or cluster, prescription records based on patient identifying information-first and last name, gender, birth date, and sometimes other information such as address or phone number. Because variations in name spelling, abbreviations, and typographic errors may exist in the patient information, PDMPs and their vendors are increasingly exploring probabilistic clustering algorithms that use fuzzy logic principles. However, there is currently no widely accepted single clustering method, and the extent of differences across states in patient risk measures resulting from different clustering methods is unknown. At the time of this study, Massachusetts, like many PDMPs at the time, used exact matching of patient information to cluster prescription records (it has since adopted a probabilistic matching method). Although an effort was made to identify additional prescription records that may not have been captured by exact matching, patients meeting the MPE threshold were identified using the exact matching method. As this approach applied to both the intervention and comparison groups, we do not expect it to have had a differential effect between the groups on changes in their outcome measures.
Conclusions
Unsolicited reporting has not been fully utilized by PDMPs to address prescription opioid misuse and abuse, in part due to limited evidence. While exploratory, the present study adds to the evidence base, addresses several methodological limitations of prior studies, and strongly suggests the differential effectiveness of unsolicited reporting on individuals who exceeded this study's MPE threshold. The measures used to evaluate baseline-follow-up period differences in both the intervention and comparison groups-included 1) number of prescriptions, 2) number of prescribers, 3) number of pharmacies, 4) quantity supplied (solid dose), 5) number of days' supply (solid dose), 6) total morphine milligram equivalents (MME; solid dose only), and 7) average daily dose. performed an intermediate step of (temporarily) enlarging the comparison pool. This was accomplished by relaxing the four prescribers and four pharmacies threshold (while still excluding patients with low numbers of prescriptions). The expanded pool involved the use of propensity score matching on a 6-to-1 ratio (i.e., six comparison individuals to each patient in the intervention group). The six nearest matches in the comparison pool for each individual in the intervention group were selected at the same time, ensuring that all comparison matches met the MPE threshold applied to the intervention group. Our analysis both assessed the comparability of the intervention and comparison groups at baseline (Tables 1 and 2) , and controlled for any residual baseline differences through the use of baseline covariates (Tables 3 and 4 ). 3. The term "solid dose" refers to any dispensed Schedule II drug product that refers to individual tablets, capsules, pills, and patches. This excludes liquids, gels, ointments, and other nonsolid quantities. 4. The specific opioid drug-specific multipliers were calculated using the following resource: http:// www.globalrph.com/opioidconverter2.htm. 5. 01 was added to variable values prior to taking the natural logarithm to avoid undefined values. 6. It is possible that some of these individuals will have legitimate reasons for meeting or exceeding the specified MPE threshold. The MPE threshold are very conservative and must include at least one opioid drug product; therefore, we expect the number of false positives to be very small. 7. Data not shown. Full results available upon request.
